{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T07:18:24Z","timestamp":1697872704194},"reference-count":27,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2012,5,1]],"date-time":"2012-05-01T00:00:00Z","timestamp":1335830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapies"],"published-print":{"date-parts":[[2012,5]]},"DOI":"10.2515\/therapie\/2012025","type":"journal-article","created":{"date-parts":[[2012,8,8]],"date-time":"2012-08-08T13:39:00Z","timestamp":1344433140000},"page":"223-230","source":"Crossref","is-referenced-by-count":4,"title":["Co-morbidit\u00e9s psychiatriques associ\u00e9es \u00e0 des fortes posologies de m\u00e9thadone (> 100 mg\/j) : analyse r\u00e9trospective d\u2019une cohorte de patients trait\u00e9s"],"prefix":"10.1016","volume":"67","author":[{"given":"C\u00e9line","family":"Eiden","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yves","family":"Leglise","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B\u00e9atrice","family":"Clarivet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Blayac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H\u00e9l\u00e8ne","family":"Peyri\u00e8re","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.2515\/therapie\/2012025_bb0625","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/BF02190738","article-title":"Methadone maintenance treatment: an update","volume":"245","author":"Bertschy","year":"1995","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"10.2515\/therapie\/2012025_bb0630","series-title":"Premiers r\u00e9sultats d\u2019une analyse de donn\u00e9es de remboursement concernant plus de 4500 patients en 2006 et 2007","first-page":"1","article-title":"Donn\u00e9es r\u00e9centes relatives aux traitements de substitution aux opiac\u00e9s","volume":"65","author":"Canarelli","year":"2009"},{"key":"10.2515\/therapie\/2012025_bb0635","first-page":"1","article-title":"The initial prescription of methadone in health establishments","volume":"60","author":"Obradovic","year":"2008","journal-title":"Tendances OFDT avril"},{"key":"10.2515\/therapie\/2012025_bb0640","unstructured":"Circulaire DGS\/DHOS n\u00b0 2002-57 du 30 janvier 2002 relative \u00e0 la prescription de la m\u00e9thadone par les m\u00e9decins exer\u00e7ant en \u00e9tablissement de sant\u00e9, dans le cadre de l\u2019initialisation d\u2019un traitement de substitution pour les toxicomanes d\u00e9pendants majeurs aux opiac\u00e9s, http:\/\/www.sante.gouv.fr"},{"key":"10.2515\/therapie\/2012025_bb0645","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S1056-8719(00)00043-5","article-title":"Methadone: a review of its pharmacokinetic\/pharmacodynamic properties","volume":"42","author":"Garrido","year":"1999","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.2515\/therapie\/2012025_bb0650","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1016\/S0755-4982(04)98772-6","article-title":"Initialisation hospitali\u00e8re d\u2019un traitement substitutif par m\u00e9thadone, recommandations de prescription","volume":"33","author":"Pons","year":"2004","journal-title":"Presse Med"},{"key":"10.2515\/therapie\/2012025_bb0655","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0013-7006(06)76190-5","article-title":"M\u00e9thadone : de la pharmacocin\u00e9tique \u00e0 la pharmacologie clinique","volume":"32","author":"Vazquez","year":"2006","journal-title":"Enc\u00e9phale"},{"issue":"11","key":"10.2515\/therapie\/2012025_bb0660","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/jama.281.11.1000","article-title":"Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial","volume":"271","author":"Strain","year":"1999","journal-title":"JAMA"},{"key":"10.2515\/therapie\/2012025_bb0665","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD002208","article-title":"Methadone maintenance at different dosages for opioid dependence","author":"Faggiano","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"key":"10.2515\/therapie\/2012025_bb0670","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1111\/j.1360-0443.2005.01232.x","article-title":"Methadone doses of 100mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers","volume":"100","author":"Donny","year":"2005","journal-title":"Addiction"},{"key":"10.2515\/therapie\/2012025_bb0675","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10550880903183042","article-title":"High dose versus moderate dose methadone maintenance: is there a better outcome?","volume":"28","author":"Fareed","year":"2009","journal-title":"J Addict Dis"},{"key":"10.2515\/therapie\/2012025_bb0680","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.drugalcdep.2005.06.005","article-title":"Therapeutic thresholds in methadone maintenance treatment: a receiver operating characteristic analysis","volume":"81","author":"Hallinan","year":"2006","journal-title":"Drug Alcohol Depend"},{"key":"10.2515\/therapie\/2012025_bb0685","series-title":"Th\u00e9saurus des interactions m\u00e9dicamenteuses, Afssaps","year":"2010"},{"key":"10.2515\/therapie\/2012025_bb0690","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1300\/J069v19n02_03","article-title":"Methadone dose and retention during treatment of heroin addicts with Axis I psychiatric comorbidity","volume":"19","author":"Maremmani","year":"2000","journal-title":"J Addict Dis"},{"key":"10.2515\/therapie\/2012025_bb0695","first-page":"5","article-title":"Correlation between hepatitis C serostatus and methadone dose requirement in 1,163 methadone-maintained patients","volume":"4","author":"Maxwell","year":"2002","journal-title":"Heroin Add & Rel Clin Probl"},{"key":"10.2515\/therapie\/2012025_bb0700","first-page":"57","article-title":"Hepatitis C infected patients and higher doses of methadone","volume":"2","author":"Okruhlica","year":"2000","journal-title":"Heroin Add & Rel Clin Probl"},{"key":"10.2515\/therapie\/2012025_bb0705","first-page":"11","article-title":"Is craving for heroin and alcohol related to low methadone dosages in methadone maintained patients?","volume":"4","author":"Lubrano","year":"2002","journal-title":"Heroin Add & Rel Clin Probl"},{"key":"10.2515\/therapie\/2012025_bb0710","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1007\/s00228-009-0706-8","article-title":"Cannabis and benzodiazepines as determinants of methadone trough plasma concentration variability in maintenance treatment: a transnational study","volume":"65","author":"Hallinan","year":"2009","journal-title":"Eur J Clin Pharmacol"},{"key":"10.2515\/therapie\/2012025_bb0715","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jad.2006.09.017","article-title":"Depression in methadone maintenance treatment patients: rate and risk factors","volume":"99","author":"Peles","year":"2007","journal-title":"J Affect Dis"},{"key":"10.2515\/therapie\/2012025_bb0720","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1521-0391.2009.00005.x","article-title":"Drug interactions of clinical importance among the opioids, methadone and buprenorphine, and other frequently prescribed medications: a review","volume":"19","author":"McCance-Katz","year":"2010","journal-title":"Am J Addict"},{"key":"10.2515\/therapie\/2012025_bb0725","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0376-8716(02)00320-4","article-title":"Cytochrome P4503A4 metabolic activity, methadone blood concentrations, and methadone doses","volume":"69","author":"Shinderman","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.2515\/therapie\/2012025_bb0730","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.pnpbp.2008.07.009","article-title":"Association of dopamine and opioid receptor genetic polymorphisms with response to methadone maintenance treatment","volume":"32","author":"Crettol","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.2515\/therapie\/2012025_bb0735","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","article-title":"QTc interval screening in methadone treatment","volume":"150","author":"Krantz","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.2515\/therapie\/2012025_bb0740","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1592\/phco.23.6.802.32186","article-title":"Dose-related effects of methadone on QT prolongation in a series of patients with torsade de pointes","volume":"23","author":"Krantz","year":"2003","journal-title":"Pharmacotherapy"},{"key":"10.2515\/therapie\/2012025_bb0745","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1743-6109.2007.00702.x","article-title":"Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment","volume":"5","author":"Hallinan","year":"2008","journal-title":"J Sex Med"},{"key":"10.2515\/therapie\/2012025_bb0750","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1300\/J069v24n02_08","article-title":"Methadone maintenance and male sexual dysfunction","volume":"24","author":"Brown","year":"2005","journal-title":"J Addict Dis"},{"key":"10.2515\/therapie\/2012025_bb0755","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2605.2007.00824.x","article-title":"Hypogonadism in men receiving methadone and buprenorphine maintenance treatment","volume":"32","author":"Hallinan","year":"2009","journal-title":"Int J Androl"}],"container-title":["Therapies"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308356?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0040595716308356?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,4,3]],"date-time":"2019-04-03T11:38:03Z","timestamp":1554291483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0040595716308356"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["S0040595716308356"],"URL":"https:\/\/doi.org\/10.2515\/therapie\/2012025","relation":{},"ISSN":["0040-5957"],"issn-type":[{"value":"0040-5957","type":"print"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}